Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Cervantes

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Gastroenterologia Y Hepatologia|January 11, 2020
Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective databaseGloria Baguena, Gianluca Pellino, Matteo Frasson, et al.
Clinical & Experimental Metastasis|April 25, 2012
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primaryDimitrios Krikelis, George Pentheroudakis, Anna Goussia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumorsJosé Baselga, Andres Cervantes, Erika Martinelli, et al.
The Oncologist|March 29, 2014
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancerRocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, et al.
Anticancer Research|April 12, 2012
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utilityAikaterini Stoyianni, Anna Goussia, George Pentheroudakis, et al.
Clinical Colorectal Cancer|July 6, 2021
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical DataPasquale Vitale, Nicoletta Zanaletti, Vincenzo Famiglietti, et al.
British Journal of Cancer|July 20, 2023
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trialMichael Friedlander, Linda Mileshkin, Janine Lombard, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2018
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpressionCarolina Martinez-Ciarpaglini, Sara Oltra, Susana Roselló, et al.
Oncotarget|December 30, 2017
mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survivalAna-Barbara García-García, M Carmen Gómez-Mateo, Rebeca Hilario, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Gastroenterologia Y Hepatologia|January 11, 2020
Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective databaseGloria Baguena, Gianluca Pellino, Matteo Frasson, et al.
Clinical & Experimental Metastasis|April 25, 2012
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primaryDimitrios Krikelis, George Pentheroudakis, Anna Goussia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumorsJosé Baselga, Andres Cervantes, Erika Martinelli, et al.
The Oncologist|March 29, 2014
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancerRocio Garcia-Carbonero, Fernando Rivera, Joan Maurel, et al.
Anticancer Research|April 12, 2012
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utilityAikaterini Stoyianni, Anna Goussia, George Pentheroudakis, et al.
Clinical Colorectal Cancer|July 6, 2021
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical DataPasquale Vitale, Nicoletta Zanaletti, Vincenzo Famiglietti, et al.
British Journal of Cancer|July 20, 2023
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trialMichael Friedlander, Linda Mileshkin, Janine Lombard, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2018
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpressionCarolina Martinez-Ciarpaglini, Sara Oltra, Susana Roselló, et al.
Oncotarget|December 30, 2017
mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survivalAna-Barbara García-García, M Carmen Gómez-Mateo, Rebeca Hilario, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
Pageof 8